Aspirin Effects on Mortality and Morbidity in Patients With Diabetes Mellitus: Early Treatment Diabetic Retinopathy Study Report 14

JAMA: The Journal of the American Medical Association

Volumn 268, Issue 10, 1992, Pages 1292-1300

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX DIFFERENCE; STROKE;

ADOLESCENT; ADULT; AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMAN; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGE; MORBIDITY; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026775578     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1992.03490100090033     Document Type: Article

References (35)

1. Heath H, Brigden WD, Canever JV, Pollock J, Kelsey J, Bloom A. Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia. 1971;7:308-315.
2. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 1975;83:733-738.
3. Kwaan HC, Colwell JA, Cruz S, Suwanwele N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med. 1972;20:235-246.
4. Colwell JA, Sagel J, Crook L, Chambus A, Laimins M. Correlation of platelet aggregation, ‘plasma factor’ activity, and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism. 1977;26:279-285.
5. Halushka PV, Lurie D, Colwell JA. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus. N Engl J Med. 1977;297:1306-1310.
6. Ziboh VA, Maruta H, Lord J, Cagel WD, Luck W. Increased biosynthesis of thromboxane A2 by diabetic platelets. Eur J Clin Invest. 1979;9:223-228.
7. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med. 1981;97:87-96.
8. Almer L, Pandolfi M, Nilsson IM. Diabetic retinopathy and the fibrinolytic system. Diabetes. 1975; 24:529-534.
9. Willis AL. An enzymatic mechanism for the antithrombotic and antihemostatic actions of aspirin. Science. 1974;183:325-337.
10. Regnault F. Rôle des plaquettes dans la pathogénie de la rétinopathie diabétique. Sem Hop Paris. 1972;48:893-902.
11. Mooney AJ. Diabetic retinopathy: a challenge. Br J Ophthalmol. 1963;47:513-520.
12. Powell EDU, Field RA. Diabetic retinopathy and rheumatoid arthritis. Lancet. 1964;2:17-18.
13. Carroll WW, Geeraets WJ. Diabetic retinopathy and salicylates. Ann Ophthalmol. 1972;4:1019-1046.
14. Bell ET. A post-mortem study of vascular disease in diabetes. Arch Pathol. 1952;53:444-455.
15. Kessler II. Mortality experience in diabetic patients. Am J Med. 1971;51:715-724.
16. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetes in the Framingham population: six-year follow-up study. Diabetes. 1974;23:105-111.
17. Raskin P. Diabetic regulation and its relationship to microangiopathy. Metabolism. 1978;27:235-251.
18. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics), I: causes and death rates. Diabetologia. 1990;33:538-541.
19. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. ETDRS design and baseline patient characteristics: ETDRS report number 7. Ophthalmology. 1991;98(suppl):741-756.
20. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology. 1991;98(suppl):757-765.
21. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(suppl):766-785.
22. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical applications of Diabetic Retinopathy Study (DRS) findings: DRS report number 8. Ophthalmology. 1991;88:583-600.
23. Early Treatment Diabetic Retinopathy Research Group. ETDRS Manual of Operations. Springfield, Va: National Technical Information Service; 1985. US Dept of Commerce publication PB85 223006/AS.
24. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300:1142-1147.
25. Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneva, Switzerland: World Health Organization; 1968.
26. Armitage P. Statistical inference. In: Statistical Methods in Medical Research. Boston, Mass: Blackwell Scientific Publications Inc; 1971:116-131.
27. Cutler SJ, Ederer F. Maximum utilization of the life table in analyzing survival. J Chronic Dis. 1958;8:699-712.
28. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
29. Cox DR. Survival models and life tables (with discussion). R Stat Soc Ser B. 1972;34:187-220.
30. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
31. Prior MJ, Prout T, Miller D, et al. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study: ETDRS report No. 6. Ann Epidemiol. In press.
32. Steering Committee of the Physicians’ Health Study Research Group. Final report of the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129-135.
33. Peto R, Gray R, Collins R. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
34. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
35. Antiplatelet Trialists’ Collaboration. Overall effects on major vascular events: subgroup issues and comparison of agents. Read before the 40th Annual Scientific Session of the American College of Cardiology; March 6, 1991; Atlanta, Ga.